Stockscreener 앱 받기
6.49
3.02%
0.19
시간 외 거래:
6.41
-0.08
-1.23%
전일 마감가:
$6.30
열려 있는:
$6.6
하루 거래량:
16,769
Relative Volume:
0.18
시가총액:
$11.71M
수익:
-
순이익/손실:
$-15.91M
주가수익비율:
-0.0141
EPS:
-460.5048
순현금흐름:
$-13.65M
1주 성능:
+8.35%
1개월 성능:
-19.48%
6개월 성능:
-57.50%
1년 성능:
+10.56%
1일 변동 폭
$6.265
$6.60
1주일 범위
$5.4701
$6.98
52주 변동 폭
$5.27
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
명칭
Quoin Pharmaceuticals Ltd Adr
전화
97299741444
주소
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
6.49 | 11.36M | 0 | -15.91M | -13.65M | -460.50 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - Sahm
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy By Investing.com - Investing.com India
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy - Investing.com
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - ChartMill
ETFs Investing in Quoin Pharmaceuticals. Ltd Sponsored ADR Stocks - TradingView — Track All Markets
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy? - Defense World
Pre Market Movers: PRAX, SPRC, QNRX Set The Pace - RTTNews
Wall Street analysts’ outlook for Quoin Pharmaceuticals Ltd ADR (QNRX) - setenews.com
US Stocks Mixed; Sea Shares Gain After Q3 ResultsMSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM) - Benzinga
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings By Investing.com - Investing.com Philippines
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - Mint
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Sahm
Zoetis (NYSE:ZTS) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Survey - Defense World
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Manila Times
Quoin Pharmaceuticals stock rises after positive pediatric trial data - Investing.com
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause - MSN
Quoin Pharmaceuticals stock rises after positive pediatric trial data By Investing.com - Investing.com UK
Quoin Pharmaceuticals announces FDA granted ODD to QRX003 - TipRanks
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Quoin Pharmaceuticals, Ltd.American Depositary Shares (Nasdaq:QNRX) Stock Quote | Pittsburgh Post-Gazette - FinancialContent
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next? - ts2.tech
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals. Ltd Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome - ChartMill
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome - ChartMill
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
QNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals Ltd Share Price ADR EACH REPR 35 ORD SPON - Hargreaves Lansdown
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals Ltd Adr (QNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):